Cyclosporin A and tacrolimus reduce T-cell polyfunctionality but not interferon-γ responses directed at cytomegalovirus

Immunology

Volumn 136, Issue 4, 2012, Pages 408-413

  Fuhrmann, Stephan ^a,b   Lachmann, Raskit ^a   Streitz, Mathias ^a   Hetzer, Roland ^c   Volk, Hans Dieter ^a   Lehmkuhl, Hans ^c   Kern, Florian ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^d BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cytomegalovirus; Flow cytometry; Solid organ transplantation; T cells

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP65; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LUNG TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84863217498     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03594.x     Document Type: Article

References (14)

1. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180:247-53.
2. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78:1373-80.
3. Cobbold M, Khan N, Pourgheysari B et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379-86.
4. Chalandon Y, Degermann S, Villard J et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood 2006; 107:389-96.
5. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357-61.
6. Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116:1655-62.
7. Gerna G, Lilleri D, Rognoni V et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009; 9:1142-50.
8. Kern F, LiPira G, Gratama JW, Manca F, Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005; 26:477-84.
9. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58.
10. Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F. Mapping T cell epitopes by flow cytometry. Methods 2003; 29:270-81.
11. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 2:65-78.
12. Fuhrmann S, Streitz M, Reinke P, Volk HD, Kern F. T cell response to the cytomegalovirus major capsid protein (UL86) is dominated by helper cells with a large polyfunctional component and diverse epitope recognition. J Infect Dis 2008; 197:1455-8.
13. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-10.
14. Betts MR, Gray CM, Cox JH, Ferrari G. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines 2006; 5:505-16.